Australian biotech Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase II clinical trial of NNZ-2591.
The study investigated NNZ-2591 in children with Angelman syndrome (AS). NNZ-2591 was safe and well tolerated as an oral liquid dose and improvements were seen in clinically important aspects of AS.
The findings were aimed at bolstering confidence in NNZ-2591’s potential to treat a range of neurodevelopmental disorders, but failed to impress, as Neuron’s share were down 5.5% at A$16.15
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze